

September 16, 2017

To,
National Securities Exchange of India Limited
Listing Department
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir,

Trading Symbol: ZOTA

Sub: Product Registration in Myanmar

Ref.: Regulation 30(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30(3) of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 this is to inform you that Company has received product registration for below mentioned two products from Myanmar.

| Name of Product | Therapeutic Category |
|---|-----------------------------|
| AMLOZED-5 (Tab. Amlodipine Besilate BP eq. to Amlodipine 5mg) | Antihypertensive |
| Z-CPM 4 (Tab. Chlorpheniramine Maleate BP 4mg) | Antihistamine (Nonsedating) |

Company shall start exporting these two products in Myanmar very soon.

This is for your information and record.

Yours faithfully,

For **Zota Health Care Limited**



Ashvin Variya
(Company Secretary & Compliance Officer)

Place: Surat

Corporate Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122